Boston Scientific Corporation News

BOSTON SCIENTIFIC CORPORATION: Boston Scientific Announces Agreement To Acquire Augmenix, Inc.

Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Augmenix, Inc., a privately-held company which has developed and commercialized the SpaceOARĀ® System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.

Metro Business Network